MiRagen, facing capital problems, plans funding raise by next summer
BOULDER — DNA therapy company miRagen Therapeutics Inc. (Nasdaq: MGEN) says it needs to raise capital by next summer or face closing down.
The Boulder pharmaceutical company posted $690,000 in revenue and a loss of 36 cents per share for the quarter, missing Wall Street consensus estimates of $1.25 million and a 30 cents per share loss, according to Seeking Alpha data.
It had an $11.23 million net loss in the period.
In its extended filings, miRagen estimated it had enough capital to keep operating through Q2 2020. Without additional fundraising, the company said it will not be able to…
SPONSORED CONTENT
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Ann Schmiesing, vice chancellor and executive vice provost for Academic Resource Management at the University…
-
TiFin Group , a Boulder-based financial technology umbrella company, has offloaded its ownership stake in…
-
Broomfield-based Premier Members Credit Union opened a new branch this week at 1425 S. Airport…
-
Ent Credit Union has joined a coalition of credit unions across the country to launch…
